论文部分内容阅读
目的:评价利拉鲁肽与二甲双胍对肥胖患者2-型糖尿病的疗效及其对微炎症状态的影响。方法:选取2012年4月—2015年11月间接诊疗的2-型糖尿病肥胖患者82例纳入研究对象,采用随机分组法,将其分为对照组40例和观察组42例;对照组患者给予二甲双胍片降血糖治疗,观察组患者在对照组基础上加用利拉鲁肽治疗,评价两组患者治疗后的体质指数(BMI)和空腹血糖(FBG)、糖化血红蛋白(Hb A1c)等指标,以及肿瘤坏死因子(TNF-α)、白介素-6(IL-6)、超敏C-反应蛋白(Hs-CRP)等炎症指标和低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)及三酰甘油酯(TG)等血脂水平的改善情况。结果:治疗后,两组患者BMI、FBG、HbA1c、TNF-α、IL-6、Hs-CRP、LDL-C、TG等指标均下降,而HDL-C值则升高,观察组患者的改善效果优于对照组(P<0.05)。结论:采用利拉鲁肽与二甲双胍治疗肥胖患者2-型糖尿病的疗效较为显著,不但能改善患者血糖血脂水平,还能改善炎症指标,其疗效优于单用二甲双胍片治疗。
OBJECTIVE: To evaluate the efficacy of liraglutide versus metformin on type 2 diabetes in obese patients and its effect on microinflammatory state. Methods: Eighty-two obese patients with type 2 diabetes mellitus diagnosed indirectly from April 2012 to November 2015 were enrolled in this study. They were divided into control group (n = 40) and observation group (n = 42) by randomization method. Patients in control group Metformin tablets were used in the treatment of hypoglycemia. The patients in the observation group were treated with liraglutide on the basis of the control group, and the body mass index (BMI), fasting blood glucose (FBG) and HbA1c were measured after treatment. And inflammatory markers such as tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and hypersensitive C-reactive protein and low density lipoprotein -C) and triglycerides (TG) and other blood lipid levels improved. Results: After treatment, the indexes of BMI, FBG, HbA1c, TNF-α, IL-6, Hs-CRP, LDL-C and TG in both groups decreased and the HDL- The effect is better than the control group (P <0.05). Conclusion: The efficacy of liraglutide and metformin in the treatment of type 2 diabetes in obese patients is more obvious. It not only can improve the level of blood glucose and blood lipid, but also improve the index of inflammation. The curative effect is better than that of metformin alone.